Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.

  title={Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.},
  author={Alberto Papi and Bradley E. Chipps and Richard Beasley and Reynold A. Panettieri and Elliot Israel and Mark Cooper and Lynn Dunsire and Allison Jeynes-Ellis and Eva Johnsson and Robert Rees and Christy Cappelletti and Frank C. Albers},
  journal={The New England journal of medicine},
BACKGROUND As asthma symptoms worsen, patients typically rely on short-acting β2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma exacerbations. The use of a fixed-dose combination of albuterol and budesonide, as compared with albuterol alone, as rescue medication might reduce the risk of severe asthma exacerbation. METHODS We conducted a multinational, phase 3, double-blind, randomized, event-driven trial to… 

Figures and Tables from this paper

Asthma-related hospitalizations after implementing SABA-free asthma management with a maintenance and anti-inflammatory reliever regimen

Preliminary real-world evidence is provided that MART/AIR with budesonide/formoterol simultaneously with SABA elimination across asthma severities is an effective asthma management strategy for reducing asthma-related hospitalizations.

Salbutamol in the Management of Asthma: A Review

The pharmacological profile of different salbutamol formulations is reviewed, focusing on their efficacy and adverse effects for its original application, asthma.

A Paradigm Shift for Asthma Care.

There is a window of opportunity just prior to an asthma exacerbation during which use of fast-acting bronchodilator + ICS may play a significant role in mitigating the risk of exacerbation.

Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children.

This review update added a new study that increased the number of people in the primary analysis from 1520 to 1774, and incorporates the most up-to-date methods to assess the likely impact of bias within the meta-analyses.

In moderate-to-severe asthma, as-needed albuterol–budesonide reduced severe exacerbations vs. albuterol alone

Albuterol-budesonide fixed-dose combination rescue inhaler for asthma and its use in children with asthma and adults with asthma is described.

The Impact of Systemic Racial Inequities on Asthma 5-6

Evaluating the efficacy and safety of tirzepatide in adults with obesity or who are overweight with one or more weight related comorbidities, not including diabetes sought to evaluate.

Updates in Hospital Medicine

Many hospitalized patients diagnosed with an acute distal DVT will have risk factors for clot extension; a therefore Direct Oral Anticoagulant (DOAC) therapy should be considered.

Advances in Evaluation and Treatment of Severe Asthma (Part One).

  • C. Fanta
  • Medicine
    The Medical clinics of North America
  • 2022

Albuterol und Budesonid steigern Effektivität bei Asthma-Exazerbation

  • DMW - Deutsche Medizinische Wochenschrift
  • 2022



Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study

This event-driven study enrolled symptomatic patients who experienced ≥1 severe asthma exacerbation in the previous year and were receiving maintenance therapy for ≥3 months prior to study entry, to determine the efficacy of albuterol in combination with budesonide as rescue therapy in patients with moderate-to-severe asthma.

Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.

In patients with mild asthma, the symptom-driven use of inhaled beclomethasone and albuterol in a single inhaler is as effective as regular use of asthma medication and is associated with a lower 6-month cumulative dose of the inhaled corticosteroid.

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.

Bud/form maintenance + relief prolonged the time to first severe exacerbation (p < 0.001), reduced severe exacerbations rate, and improved symptoms, awakenings, and lung function compared with both fixed dosing regimens.

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

Budesonide/formoterol single inhaler therapy has the potential to provide a complete asthma management approach with one inhaler, demonstrating a high level of efficacy in patients with moderate to severe asthma.

What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever?

The data confirm that patients with asthma treated with budesonide/formoterol MART achieved the same or better asthma symptom control compared with ICS/LABA plus SABA regimens at similar or higher ICS doses, with consistently lower rates of exacerbations and considerably lower annual requirement for oral corticosteroids.

Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma.

Among Black and Latinx adults with moderate-to-severe asthma, provision of an inhaled glucocorticoid and one-time instruction on its use, added to usual care, led to a lower rate of severe asthma exacerbations.

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations

Budesonide/ formoterol for maintenance and relief reduces asthma exacerbations and maintains similar daily asthma control at a lower overall drug load compared with fixed‐dose salmeterol/fluticasone and budesonide/formoterol.

Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study

Fluticasone/formoterol was well tolerated and had a good safety profile that was similar to fluticas one/salmeterol, and has a more rapid onset of action, reflecting the faster bronchodilatory effects of formoterol compared with those of salmeterol.